Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[EX Q]: Paragraph: "There was no discussion of costs of vegetable consumption. Although this could be considered general knowledge, mention of typical costs for vegetables would have been a nice addition. The research on which this story was based compared increasing amounts of vegetable (or fruit and vegetable, or fruit) intake with intake of 0 – 1.1 servings per day. The study actually only found a statistically significant improvement in the rate of decline for individuals eating 2.5 or more servings of vegetables per day. The story said the effect came with “more than two servings of vegetables per day"" – which is too imprecise. In addition, the benefit to be obtained through increased vegetable consumption was characterized as people appearing 5 years younger at the end of the six-years or having 40 percent less mental decline   It would have been helpful to provide some idea of the difference this actually represents. The five-year appearance change estimate comes directly from the discussion section of the research paper though the authors of that paper did not provide details on how they arrived at the estimate. This story was not actually about a treatment per se but rather about the possible association between an eating pattern and age-related decline in function. This story reported on a prospective study of cognitive decline in older individuals. Although it did not explicitly mention the nature of the study design, the story included the caveat that the findings don’t prove that vegetables reduce mental decline, but add to mounting evidence pointing in that direction. The story would have been stronger if it had included information on the methodology for assessing dietary intake. No obvious elements of disease-mongering The story used several different sources. This story did not discuss other means to delay or diminish the rate of cognitive decline with age. This story reported on a study of vegetable and fruit consumption in older adults in the Chicago area – vegetables and fruits that are clearly widely available. The story begins, ""New research on vegetables and aging gives mothers another reason to say 'I told you so.' ""  Clearly, this is not a new idea, but the story is about new evidence. Because the story used multiple sources, it does not appear to have relied solely or largely on a news release." Claim: Study: Vegetables may keep brains young
[EX A]: This story presented the results from a recent study which found a slower decline in mental sharpness in older people who ate 2.5 or more servings of vegetables per day than in people who ate 0 – 1.1 servings of vegetables per day. The story said the effect came with “more than two servings of vegetables per day” – which is too imprecise. In addition, the benefit to be obtained through increased vegetable consumption was characterized as people appearing five years younger at the end of the six-years or having 40 percent less mental decline. It would have been more helpful to frame for the reader the amount of mental decline typically seen in the age group studied, what the decline represents in terms of function, and the amount of potential for benefit to be gained through increased vegetable consumption. The five-year appearance change estimate comes directly from the discussion section of the research paper though the authors of that paper did not provide details on how they arrived at the estimate. It was useful that the story pointed out that the research found an association between vegetable intake but not for fruit intake. Although the standard wisdom is to eat a diet rich in fruits and vegetables, this story provides a distinction between these two for readers to consider. It would have been useful for the story to provide a little more clarity about the definition of ‘vegetable’ for the reader. This study was interesting in that, unlike the USDA, it did not include potatoes in its vegetable count. In addition, it should be pointed out that whereas the FDA's Dietary Guidelines for Americans recommends the equivalent of four to 13 servings a day of vegetables and fruit in a typical 2,000 calorie diet, the benefit in this study was seen at a much lower level –  2.5 servings/day of vegetable consumption.

[EX Q]: Paragraph: House Speaker Jose Oliva was unsparing in his criticism of what he called the “healthcare industrial complex,” including drug companies, hospitals and medical device companies that he said were “the great robber-barons of our time.” Oliva sought to build on some of health care initiatives of last year’s legislative session, including passage of a first-in-the-nation drug importation bill. “We did not choose healthcare as our priority,” he said. “No, it chose us. It chose us through the sheer audacity of the defenders of the status quo.” With a presidential election looming this fall, fierce partisan divides could influence the work of lawmakers. But an air of collegiality prevailed Tuesday, as bouquets festooned the chambers and the Capitol halls and rotundas pulsed with activity. Opening day was also important for lobbyists and the activists who seek to influence lawmakers and the legislation that will be crafted over the 60 days the Legislature has to complete its business before adjourning. While DeSantis enjoys strong relationships with lawmakers — particularly his fellow Republicans who run both chambers of the statehouse — he may not necessarily get everything he wants during his second year as the state’s chief executive. His $91.4 billion budget calls for major spending on the environment and education — including a nearly $1 billion outlay for teacher raises and bonuses. Some fiscally conservative lawmakers said they would give the spending intense scrutiny. On the eve of the Legislature’s opening day, thousands of educators and their allies descended on the Capitol to draw attention to the governor’s plan, calling it flawed because of potential pay inequities and because veteran educators and non-teaching school employees would be left out. Some key Republicans have also cast doubt on the governor’s plan to require employers to use a federally operated electronic database known as E-Verify to check the immigration status of workers. E-Verify has been opposed by agriculture, construction, tourism interests and other industries that rely on immigrant labor. Hundreds of bills await, encompassing education spending, health care, the environment and public safety — as well as approving the billions of dollars required to keep the country’s third-most populous state operating day to day. Legislative Democrats are pushing for stronger gun control measures, but face long odds to win over their Republican colleagues. Addressing a joint session of the state House and Senate during his State of the State address, DeSantis urged cooperation — particularly when it comes to approving his agenda on the environment and education. “This is Florida’s season of opportunity,” DeSantis told lawmakers. “We have the chance to build on a strong foundation, the chance to face the challenges before us and the chance to leave a legacy of success that will benefit our people now and in the future.” Rep. Chris Sprowls, a Republican who’s next in line to be House speaker, commended DeSantis for the sweep of his speech -- covering priorities, he said, that were crucial to Florida’s future. “The members of the House want to help the governor because we believe in the same thing,” Sprowls said. However, Sprowls declined to discuss the merits of specific legislation proposed by the governor, saying that task will be undertaken in the days and weeks to come. And while the governor’s agenda appeared “bright,” he said, “nothing is ever a slam dunk.” In his opening remarks, Senate President Bill Galvano, a Republican, reminded lawmakers of their weighty responsibility. “As we go into this session let us continue to show our constituents that we can exchange and debate ideas while maintaining civility and decorum,” he told the chamber. “That we can problem solve together. That we can put aside personalities and politics for good policy. And, that we are not a microcosm of Washington, D.C., but instead will continue to be an example for Washington, D.C.” Claim: Florida Legislature sets sights on education, health care.
[EX A]: Florida lawmakers signaled that they would likely tackle education spending and health care costs but might seek to avoid a battle over forcing employers to verify the immigration status of workers, as the 2020 legislative session began Tuesday.

[EX Q]: Paragraph: The article is silent on the price of Rituxan. Since the company is investing a significant sum to research an additional use, the price is worth mentioning. The article does a good job of sketching the benefits shown in this research. Focusing on the clinical endpoint of relapse, and using percentages of relapse with the drug and the placebo, makes it easy for readers to understand. The article explores the issue of whether Rituxan may suppress the immune response too much, making the patient vulnerable to other diseases. It also explains how this effect has been observed in the drug Tysabri, a different immune suppressant used for MS. This article is based on published results of a Phase II trial published in the New England Journal of Medicine. The news article does a decent job emphasizing the preliminary nature of the findings, and that larger trials are needed to ensure safety, efficacy and long-term benefits. The article does nothing to exaggerate the severity or consequences of MS. The reporter draws on the journal article and the accompanying editorial. Sources interviewed include the primary author, one medical expert representing the National Multiple Sclerosis Society and one clinician who treated some patients in the study but was not an author. This is sufficient sourcing. It is worth pointing out here, however, that Genentech and Biogen Idec, makers of Rituxan, are “Corporate Star” supporters of the National Multiple Sclerosis Society. The article states that six other drugs, all with shortcomings, are available to treat relapsing-remitting MS. The article makes clear that the drug is currently on the market and approved for other uses. But it did not state whether Rituxan is, or may become, used off-label for relapsing-remitting MS. And, as noted in our summary comment below, there are issues surrounding off-label use that could have been addressed. The article makes clear that the drug is on the market and used for related conditions, but its use in relapsing-remitting MS patients is being explored in this research. There is no evidence the article draws from a press release. Claim: MS therapy shows promise in test
[EX A]:
This news report does a solid job describing the findings of a Phase II study into the use of Rituxan for relapsing-remitting MS. It includes the necessary caveats about the study being preliminary and the need for bigger, longer-term studies to validate the findings. The evidence is reported adequately, and the sourcing is sufficient. The study itself is most important, however, because it appears to verify the important role of B-cells in the development of MS. Since most current MS drugs target T-cells, the implications of these findings for development of new treatments are significant. By focusing on the clinical results of a small trial rather than the important discovery about the role of B cells, the article may invite people with relapsing-remitting MS to wonder whether they could, or should, try to use this drug, which is on the market and approved for other uses, off-label. Other reporters asked sources whether this would be a good idea. Their stories included the useful caution that the drug should not be used off-label at this time. This story would have been better if it had too.